Bellicum Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Corporate Update
- Management to host webcast and conference call on Wednesday,
The live call may be accessed by dialing 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website following the call.
About
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T and allogeneic cell therapies. Bellicum’s lead GoCAR-T® candidate, BPX-601, is designed to be a more efficacious CAR-T cell product capable of overriding key immune inhibitory mechanisms. More information can be found at www.bellicum.com.
Source:
Investors:
Managing Director
Westwicke IR
858-356-5932
Robert.uhl@westwicke.com
Media:
Senior Vice President
Westwicke PR
646-677-1839
sean.leous@icrinc.com
Source: Bellicum Pharmaceuticals, Inc.